Biogen drops controversial Alzheimer’s drug Aduhelm to focus on Leqembi, experimental treatments

[ad_1] The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023. Vanessa Leroy | Bloomberg | Getty Images Biogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer’s drug Aduhelm to refocus the company’s efforts to treat the memory-robbing disease.  The biotech company will focus on rolling…

Read More

GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost

[ad_1] Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020.  Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or $1.5 billion,…

Read More

Norway’s giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club

[ad_1] A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023.  George Frey | Reuters Norway’s giant wealth fund, the world’s largest, touted the possibility that Danish drugmaker Novo Nordisk and U.S. rival Eli…

Read More

Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain

[ad_1] A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston on Oct. 23, 2019. Brian Snyder | Reuters Vertex Pharmaceuticals on Tuesday said its experimental painkiller, which is being tested as an alternative to addictive opioids, significantly decreased post-surgery pain in late-stage trials The drug, known as VX-548, did not…

Read More

Pfizer beats earnings estimates as declining Covid business loses less revenue than expected

[ad_1] Pfizer on Tuesday posted a surprise adjusted fourth-quarter profit, as the company’s declining Covid business loss less revenue than expected. The company reversed roughly $3.5 billion in revenue related to the expected return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. government. That hit is less than the $4.2 billion Pfizer…

Read More